Medical technology company Intuitive Surgical (NASDAQ: ISRG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 23% year on year to $2.77 billion. Its non-GAAP profit of $2.50 per share was 18.7% above analysts’ consensus estimates.

Is now the time to buy ISRG? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake of newer systems like da Vinci 5, which further lifted overall utilization.

Looking ahead, management expects ongoing investments in digital infrastructure, artificial intelligence, and expanded reimbursement policies to drive growth in 2026. Rosa emphasized that Intuitive’s innovation roadmap is “foundational to our long-term digital and AI roadmap where we expect to add telesurgery, deeper decision support and augmented dexterity.” CFO Jamie Samath noted the company is raising its full-year procedure growth outlook slightly, while remaining cautious on potential headwinds from tariffs, higher input costs, and ongoing market challenges in China and Japan.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to robust adoption of next-generation platforms, increased procedure volumes in key segments, and progress in global market access initiatives.

• Procedure growth drivers: Strong uptake of da Vinci 5 and Ion platforms fueled double-digit procedure gains, with da Vinci 5 utilization outpacing legacy systems and Ion procedures up 39%. After-hours and weekend usage also expanded, supporting higher throughput in U.S. hospitals.

• International market momentum: Outside the U.S., procedure growth was led by general surgery and gynecology, especially in India, Canada, the U.K., Korea, and Taiwan. However, management cited ongoing pricing and competitive pressures in China and slow recovery in Japan, despite new reimbursement policies set to go into effect mid-year.

• Product innovation impact: The broad launch of Force Feedback instrumentation and the SP stapler contributed to higher revenue per procedure and expanded the addressable market. Management also highlighted early clinical evidence suggesting improved surgical outcomes with da Vinci technology for procedures like appendectomy.

• Digital and AI initiatives: Continued investment in data infrastructure and My Intuitive+ digital platform underpins the company’s AI roadmap. Management outlined a vision for future capabilities, including decision support, telesurgery, and automation, with da Vinci 5’s data-capture capabilities described as a competitive advantage.

• Leadership transition: Dr. Myriam Curet is retiring as Chief Medical Officer, succeeded by Dr. Jamie Wong, who brings deep clinical experience and will oversee clinical evidence generation, training, and reimbursement efforts globally.

Drivers of Future Performance

Intuitive Surgical’s updated outlook is anchored by continued innovation, expanded reimbursement, and scaling of digital technologies, while the company remains mindful of macro and regulatory headwinds.

• Innovation-led revenue expansion: Management believes differentiated features in da Vinci 5 and the expanding SP and Ion platforms will allow revenue growth to outpace procedure growth, citing accretive pricing, higher integration, and new device launches as contributors.

• International reimbursement and access: New reimbursement for additional procedures in Japan and ongoing efforts in China to establish favorable charge codes are expected to support future growth outside the U.S., though timelines remain uncertain and management remains cautious given local challenges.

• Margin management and cost risks: CFO Jamie Samath noted that gross margin guidance reflects both ongoing cost reduction initiatives and rising input prices (e.g., memory, freight, tariffs). Management is focused on leveraging fixed overhead and optimizing product mix, while monitoring supply chain and macroeconomic risks.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) the pace of adoption for recently launched products such as Force Feedback instruments and the SP stapler, (2) the impact of new reimbursement policies and expanded indications in key international markets, and (3) the rollout and utilization of digital and AI-enabled features. Additional signposts include Intuitive’s ability to sustain innovation-led revenue growth and navigate input cost pressures.

Intuitive Surgical currently trades at $452.08, in line with $452 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.